These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Gales AC; Sader HS; Jones RN Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482 [TBL] [Abstract][Full Text] [Related]
23. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]
24. [Dalbavancin breakpoints and recommendations for in vitro study of its activity]. Cantón R; Díez-Aguilar M; Morosini MI Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():15-21. PubMed ID: 28129815 [TBL] [Abstract][Full Text] [Related]
25. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times. Di Pilato V; Ceccherini F; Sennati S; D'Agostino F; Arena F; D'Atanasio N; Di Giorgio FP; Tongiani S; Pallecchi L; Rossolini GM Diagn Microbiol Infect Dis; 2020 Feb; 96(2):114901. PubMed ID: 31761480 [TBL] [Abstract][Full Text] [Related]
26. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923 [TBL] [Abstract][Full Text] [Related]
27. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152 [TBL] [Abstract][Full Text] [Related]
28. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421 [TBL] [Abstract][Full Text] [Related]
29. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Esposito S; Noviello S; Leone S Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080 [TBL] [Abstract][Full Text] [Related]
30. In vitro activity of dalbavancin against staphylococci isolated in Istanbul, Turkey. Aktas G; Derbentli S Chemotherapy; 2010; 56(6):444-7. PubMed ID: 21088395 [TBL] [Abstract][Full Text] [Related]
31. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793 [TBL] [Abstract][Full Text] [Related]
32. Dalbavancin: a review for dermatologists. Scheinfeld N Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861 [TBL] [Abstract][Full Text] [Related]
33. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Soriano A; Rossolini GM; Pea F Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465 [No Abstract] [Full Text] [Related]
34. Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report. Guzek A; Suwalski G; Tomaszewski D; Rybicki Z J Cardiothorac Surg; 2018 Jan; 13(1):3. PubMed ID: 29304832 [TBL] [Abstract][Full Text] [Related]
35. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Andes D; Craig WA Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987 [TBL] [Abstract][Full Text] [Related]
36. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033 [TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. Bowker KE; Noel AR; MacGowan AP J Antimicrob Chemother; 2006 Oct; 58(4):802-5. PubMed ID: 16891629 [TBL] [Abstract][Full Text] [Related]
38. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Goldstein BP; Jones RN; Fritsche TR; Biedenbach DJ Diagn Microbiol Infect Dis; 2006 Feb; 54(2):83-7. PubMed ID: 16458124 [TBL] [Abstract][Full Text] [Related]